Collaboration Agreements - Narrative (Details) $ in Thousands |
1 Months Ended | 6 Months Ended | |
|---|---|---|---|
|
Mar. 31, 2024
target
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Long-term deferred revenue | $ 4,000 | $ 44,509 | |
| Deferred revenue, deductions | 8,194 | ||
| Bristol Myers Squibb Company ("BMS") | Amended Collaboration Agreement 2019 | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Agreement extension period, options to extend | 2 years | ||
| Number of gene targets | target | 3 | ||
| Long-term deferred revenue | $ 32,300 | $ 44,500 |